IP Library Patent Application 13145875
Patent Application
App. No. 13/145,875

COMPOSITIONS, KITS AND METHODS FOR DETERMINING PLASMIN ACTIVITY

Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US None
App. No.
13/145,875
Abstract

Compositions, kits, and methods for determining plasmin activity using a fluorogenic peptide substrate are provided.

Claims (51)

1 . A compound of the formula:

R m -[A n 3 A 2 A 1 ]-X   (I)

wherein

A 1 is Lys; A 2 is Phe; A 3 is an amino acid residue;

R is pyroglutamate or an N-terminal protecting group;

X is a fluorogenic group;

m is 0 or 1; and

n is an integer ≧0.

2 . The compound of claim 1 , wherein the fluorogenic group is selected from the group consisting of: 4-(substituted) coumarin, coumarin derivatives, hydroxy allyloxypropyl napthalimide quat, 4-methoxy-N-(3-N′N′-dimethylaminopropyl) napthalimide, 2-hydroxy-3-allyloxypropyl quat, 8-(3-vinylbenzyloxy)-1,3,6-pyrene trisulfonic acid, 8-(4-vinylbenzyloxy)-1,3,6-pyrene trisulfonic acid, 8-(allyloxy)-1,3,6-pyrene trisulfonic acid, 1-(substituted) naphthalene, 9-(substituted) anthracene, 2-(substituted) quinoline monohydrochloride, 2-(substituted) benzimidazole, 5-(substituted) fluorescein, 3-(substituted)-6,7-dimethoxy-1-methyl-2(1H)-quinoxazolinone, mixtures thereof and derivatives thereof.

3 . The compound of claim 1 , wherein the fluorogenic group is 7-amino-4-methylcoumarin.

4 . The compound of claim 1 , wherein R is pyroglutamate.

5 . The compound of claim 1 , wherein the N-terminal protecting group is selected from the group consisting of: an acyl protecting group, an aromatic urethane protecting group, and an aliphatic urethane protecting group.

6 . The compound of claim 1 , wherein the N-terminal protecting group is succinyl or methoxysuccinyl.

7 . The compound of claim 5 , wherein the acyl protecting group is selected from the group consisting of: succinyl, methoxysuccinyl, acetyl, benzoyl, and trifluoroacetyl.

8 . The compound of claim 5 , wherein the aromatic urethane protecting group is benzyloxycarbonyl.

9 . The compound of claim 5 , wherein the aliphatic urethane protecting group is tert-butoxycarbonyl or adamantyloxycarbonyl.

10 . The compound of claim 1 , wherein n=0.

11 . The compound of claim 1 , wherein m=1, wherein, n=0, wherein R is pyroglutamate, wherein X is 7-amino-4-methylcoumarin.

12 . A trifluoroacetyl derivative of the compound of claim 1 .

13 . A method for determining an activity of a plasmin, the method comprising:

contacting the plasmin with a compound of the formula:

R m -[A n 3 A 2 A 1 ]-X   (I)

wherein

A 1 is Lys; A 2 is Phe; A 3 is an amino acid residue;

R is pyroglutamate or an N-terminal protecting group;

X is a fluorogenic group;

m is 0 or 1; and

n is an integer ≧0.

14 . The method of claim 13 , wherein n=0, wherein R is pyroglutamate, wherein X is 7-amino-4-methylcoumarin.

15 . The method of claim 13 , wherein the plasmin is prepared from a plasma-derived plasminogen or a recombinant plasminogen.

16 . The method of claim 13 further comprising determining an amount of at least one of R-[A n 3 A 2 A 1 ] and X produced by the reaction between the plasmin and the compound represented by the formula (I), wherein the activity of the plasmin is determined on the basis of the amount of at least R-[A n 3 A 2 A 1 ], X, or both.

17 . The method of claim 13 further comprising determining an amount of X produced by the reaction between the plasmin and the compound represented by the formula (I), wherein the activity of the plasmin is determined on the basis of the amount of X.

18 . The method of claim 13 further comprising determining the activity of the plasmin based on the difference in fluorescence between the X formed and the original compound.

19 . A method of determining pharmacokinetic of a plasmin, the method comprising:

contacting the plasmin with a compound of the formula:

R m -[A n 3 A 2 A 1 ]-X   (I)

wherein

A 1 is Lys; A 2 is Phe; A 3 is an amino acid residue;

R is pyroglutamate or an N-terminal protecting group;

X is a fluorogenic group;

m is 0 or 1; and

n is an integer ≧0, wherein the plasmin is obtained from a biological sample from a subject administered with the plasmin.

20 . A method for determining a molecule that affects plasmin activity, the method comprising:

contacting the molecule with the plasmin in the presence of a compound of the formula:

R m -[A n 3 A 2 A 1 ]-X   (I)

wherein

A 1 is Lys; A 2 is Phe; A 3 is an amino acid residue;

R is pyroglutamate or an N-terminal protecting group;

X is a fluorogenic group;

m is 0 or 1; and

n is an integer ≧0.

Assignments (4)
RELEASE OF SECURITY INTEREST Recorded Feb 6, 2017
From: DEUTSCHE BANK AG NEW YORK BRANK
To: GRIFOLS THERAPEUTICS INC.; GRIFOLS SHARED SERVICES NORTH AMERICA INC.; GRIFOLS DIAGNOSTIC SOLUTIONS INC.
Reel/Frame 041638/0527 →
SECURITY AGREEMENT Recorded Feb 27, 2014
From: GRIFOLS INC.; GRIFOLS THERAPEUTICS INC.; GRIFOLS-CHIRON DIAGNOSTICS CORP.
To: DEUTSCHE BANK AG NEW YORK BRANCH, AS COLLATERAL AGENT
Reel/Frame 032367/0001 →
CHANGE OF NAME Recorded Jun 18, 2013
From: TALECRIS BIOTHERAPEUTICS, INC.
To: GRIFOLS THERAPEUTICS INC.
Reel/Frame 030650/0819 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 14, 2011
From: CRUZ, MARIA; VANDERBERG, PETE; YARBROUGH, KEVIN
To: TALECRIS BIOTHERAPEUTICS, INC.
Reel/Frame 026902/0767 →